Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives $4.50 Consensus Target Price from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has been given a consensus recommendation of “Hold” by the five brokerages that are covering the company, MarketBeat reports. Three investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1 year price target among analysts that have covered the stock in the last year is $4.50.

MIST has been the subject of several recent analyst reports. HC Wainwright upgraded shares of Milestone Pharmaceuticals to a “buy” rating and set a $5.00 price objective for the company in a report on Thursday, June 5th. Wells Fargo & Company initiated coverage on shares of Milestone Pharmaceuticals in a research note on Thursday. They set an “overweight” rating and a $4.00 price target on the stock.

Milestone Pharmaceuticals Stock Up 2.6%

MIST opened at $1.96 on Thursday. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 4.06. Milestone Pharmaceuticals has a 1-year low of $0.63 and a 1-year high of $2.75. The stock has a market cap of $166.59 million, a PE ratio of -2.33 and a beta of 0.60. The stock’s fifty day simple moving average is $1.70 and its 200 day simple moving average is $1.55.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Tuesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.02). As a group, research analysts expect that Milestone Pharmaceuticals will post -0.62 earnings per share for the current year.

Institutional Investors Weigh In On Milestone Pharmaceuticals

A number of large investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC grew its position in Milestone Pharmaceuticals by 553.5% in the 2nd quarter. Valeo Financial Advisors LLC now owns 130,699 shares of the company’s stock valued at $254,000 after purchasing an additional 110,699 shares during the period. Raymond James Financial Inc. increased its position in shares of Milestone Pharmaceuticals by 30.1% during the second quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock valued at $84,000 after buying an additional 10,000 shares during the period. XTX Topco Ltd increased its position in shares of Milestone Pharmaceuticals by 209.5% in the second quarter. XTX Topco Ltd now owns 160,963 shares of the company’s stock worth $312,000 after purchasing an additional 108,959 shares during the last quarter. Creative Planning grew its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock valued at $45,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Simplify Asset Management Inc. boosted its stake in shares of Milestone Pharmaceuticals by 16.5% during the second quarter. Simplify Asset Management Inc. now owns 990,000 shares of the company’s stock valued at $1,921,000 after purchasing an additional 140,000 shares during the period. 86.18% of the stock is currently owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.